D. Yapp

发表

Evaluation of 18F-EF5 for detection of hypoxia in localized adenocarcinoma of the prostate

Carlos F. Villamil, F. Bénard, M. McKenzie, 2021, Acta oncologica.

Spatially Specific Liposomal Cancer Therapy Triggered by Clinical External Sources of Energy

D. Yapp, Courtney van Ballegooie, A. Man, 2019, Pharmaceutics.

Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.

I. Tai, M. Bally, D. Strutt, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Overview of the JET results

P. Arena, A. Thompson, Alfredo Pironti, 2015 .

Single step 18F-labeling of dimeric cycloRGD for functional PET imaging of tumors in mice.

Zhibo Liu, Kuo-Shyan Lin, D. Perrin, 2013, Nuclear medicine and biology.

Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine

M. Bally, M. Verreault, A. Yung, 2011, BMC Cancer.

Characterization of cationic liposome formulations designed to exhibit extended plasma residence times and tumor vasculature targeting properties.

M. Bally, E. Ho, E. Ramsay, 2010, Journal of pharmaceutical sciences.

Irinophore C, a Novel Nanoformulation of Irinotecan, Alters Tumor Vascular Function and Enhances the Distribution of 5-Fluorouracil and Doxorubicin

M. Bally, A. Yung, P. Kozlowski, 2008, Clinical Cancer Research.

Applications for Drug Development

M. Bally, M. Webb, D. Yapp, 2016, Handbook of Small Animal Imaging.

Non‐invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18F‐EF5 and positron emission tomography

M. Gleave, C. Koch, T. Ruth, 2007, BJU international.

Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18 FEF 5 and positron emission tomography

M. Gleave, C. Koch, T. Ruth, 2007 .

4‐Hydroxy‐N‐methylproline

J. Steed, P. Houghton, D. Yapp, 2002 .

HACE1 blocks HIF1α accumulation under hypoxia in a RAC1 dependent manner

Christopher S. Hughes, P. Sorensen, J. Maris, 2021, Oncogene.

A new 18F-heteroaryltrifluoroborate radio-prosthetic with greatly enhanced stability that is labelled by 18F–19F-isotope exchange in good yield at high specific activity

F. Bénard, Zhibo Liu, D. Perrin, 2014 .

Dual mode fluorescent (18)F-PET tracers: efficient modular synthesis of rhodamine-[cRGD]2-[(18)F]-organotrifluoroborate, rapid, and high yielding one-step (18)F-labeling at high specific activity, and correlated in vivo PET imaging and ex vivo fluorescence.

Zhibo Liu, D. Perrin, D. Yapp, 2014, Bioconjugate chemistry.

Kit-like 18F-labeling of RGD-19F-arytrifluroborate in high yield and at extraordinarily high specific activity with preliminary in vivo tumor imaging.

Zhibo Liu, D. Perrin, D. Yapp, 2013, Nuclear medicine and biology.

Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions.

Michael I Webb, C. Walsby, Bo Wu, 2013, Chemistry.

Comparison of bifunctional chelates for 64Cu antibody imaging

M. Gleave, P. Jurek, G. Kiefer, 2010, European Journal of Nuclear Medicine and Molecular Imaging.

Imaging Tumor Vasculature Noninvasively with Positron Emission Tomography and RGD Peptides Labeled with Copper 64 Using the Bifunctonal Chelates DOTA, Oxo-DO3A. and PCTA

E. Boros, P. Jurek, G. Kiefer, 2013, Molecular imaging.

(68)Ga small peptide imaging: comparison of NOTA and PCTA.

E. Boros, P. Jurek, G. Kiefer, 2012, Bioconjugate chemistry.

An organotrifluoroborate for broadly applicable one-step 18F-labeling.

F. Bénard, Jinhe Pan, Maral Pourghiasian, 2014, Angewandte Chemie.

Evaluation of novel bifunctional chelates for the development of Cu-64-based radiopharmaceuticals.

M. Gleave, P. Jurek, G. Kiefer, 2008, Nuclear medicine and biology.

Abstract 5261: Irinophore C, a liposomal formulation of irinotecan, has anti-vascular effects in primary tumors of colorectal cancer grown orthotopically in mice

D. Owen, S. Gill, I. Tai, 2012 .

Nitroimidazole-Containing H2dedpa and H2CHXdedpa Derivatives as Potential PET Imaging Agents of Hypoxia with (68)Ga.

Jinhe Pan, C. Orvig, B. Patrick, 2015, Inorganic chemistry.

PEG Conjugated Zein Nanoparticles for In Vivo Use

M. Bally, D. Yapp, Courtney van Ballegooie, 2022, Pharmaceutics.

Radiosensitization of a mouse tumor model by sustained intra-tumoral release of etanidazole and tirapazamine using a biodegradable polymer implant device.

S. Lehnert, D. Yapp, D. Lloyd, 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Tumor radiosensitization by sustained intratumoral release of bromodeoxyuridine.

S. Lehnert, D. Yapp, J. Zhu, 1999, Cancer research.

Tumor treatment by sustained intratumoral release of cisplatin: effects of drug alone and combined with radiation.

S. Lehnert, D. Yapp, D. Lloyd, 1997, International journal of radiation oncology, biology, physics.

An overview of JET results

H. T. Kim, J. R. Martin-Solis, P. A. Simmons, 1989 .

Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.

S. C. Chafe, A. Bashashati, S. Shah, 2019, Gastroenterology.

Synthesis and characterization of new disulfoxides, and their Ru complexes

B. Patrick, D. Yapp, L. Huxham, 2020 .

RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga.

E. Boros, C. Orvig, M. Adam, 2012, Nuclear medicine and biology.

The potentiation of the effect of radiation treatment by intratumoral delivery of cisplatin.

S. Lehnert, D. Yapp, D. Lloyd, 1998, International journal of radiation oncology, biology, physics.

In vivo measurement of the hypoxia marker EF5 in Shionogi tumours using 19F magnetic resonance spectroscopy

A. Yung, P. Kozlowski, M. Hoff, 2008, International journal of radiation biology.

Functional Imaging of Oxidative Stress with a Novel PET Imaging Agent, 18F-5-Fluoro-l-Aminosuberic Acid

Christine A. Morton, Brian D. Lee, P. Schaffer, 2014, The Journal of Nuclear Medicine.

A simple route to [11C]N-Me labeling of aminosuberic acid for proof of feasibility imaging of the x(C)⁻ transporter.

V. Sossi, F. Bénard, P. Schaffer, 2014, Bioorganic & medicinal chemistry letters.

Synthesis and characterization of dithioethers, and their RuII and RuIII complexes

B. Patrick, D. Yapp, B. James, 2019, Inorganica Chimica Acta.

Synthesis, characterization, and biological studies of emissive rhenium–glutamine conjugates

T. Storr, D. Yapp, Y. Mikata, 2013, JBIC Journal of Biological Inorganic Chemistry.

Synthesis and structural characterization of cis-dichlorotetrakis(tetramethylenesulfoxide-S)ruthenium(II) and mer-trichlorotris(tetrahydrothiophene)ruthenium(III)

S. Rettig, D. Yapp, B. James, 1990 .

Induction of Cytotoxicity in Pyridine Analogues of the Anti-metastatic Ru(III) Complex NAMI-A by Ferrocene Functionalization.

M. Bally, Changhua Mu, C. Walsby, 2016, Inorganic chemistry.

Gold–Protein Composite Nanoparticles for Enhanced X-ray Interactions: A Potential Formulation for Triggered Release

A. Pallaoro, M. Bally, B. Gates, 2021, Pharmaceutics.

BIDENTATE SULFOXIDE COMPLEXES OF RUTHENIUM(II) AND THEIR PRELIMINARY BIOLOGICAL ASSESSMENT IN VITRO

S. Rettig, D. Yapp, B. James, 1997 .

Autophagy Inhibition Augments the Anticancer Effects of Epirubicin Treatment in Anthracycline-Sensitive and -Resistant Triple-Negative Breast Cancer

J. Xu, S. Chittaranjan, K. Gelmon, 2014, Clinical Cancer Research.

Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.

M. Bally, M. Verreault, D. Strutt, 2012, Journal of Controlled Release.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2

A. Weng, S. Vacher, L. weiswald, 2017, Molecular Cancer Therapeutics.

Suppression of VEGF secretion and changes in glioblastoma multiforme microenvironment by inhibition of Integrin-linked kinase (ILK)

D. Huntsman, S. Dedhar, M. Bally, 2008, Molecular Cancer Therapeutics.

The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth

C. Scudamore, D. Owen, A. Buczkowski, 2016, Angiogenesis.

Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma

C. Scudamore, D. Owen, A. Buczkowski, 2010, British Journal of Cancer.

Assessment of vessel size by MRI in an orthotopic model of human pancreatic cancer

Piotr Kozlowski, Andrew Yung, J. Flexman, 2008, 2008 30th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

Hypoxia in the Androgen-Dependent Shionogi Model for Prostate Cancer at Three Stages1

M. Gleave, C. Koch, M. Bowden, 2004, Radiation research.

Lipid-based nanoformulation of irinotecan: dual mechanism of action allows for combination chemo/angiogenic therapy.

M. Bally, M. Verreault, D. Yapp, 2011, Nanomedicine.

Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutations

Christopher S. Hughes, Scott D. Brown, R. Holt, 2020, bioRxiv.

Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin

K. Gelmon, M. Bally, M. Verreault, 2007, Breast Cancer Research and Treatment.

Overexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress

V. Sossi, M. Bally, A. Yung, 2016, Scientific Reports.

The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion

D. Yapp, Clarissa C. Pasiliao, D. Schaeffer, 2015, BMC Cancer.

Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.

M. Bally, M. Verreault, M. Wehbe, 2015, Journal of controlled release : official journal of the Controlled Release Society.

Using a Microfluidics System to Reproducibly Synthesize Protein Nanoparticles: Factors Contributing to Size, Homogeneity, and Stability

Byron D. Gates, B. Gates, I. Andreu, 2019, Processes.

The Phosphoinositide-Dependent Kinase-1 Inhibitor 2-Amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) Prevents Y-Box Binding Protein-1 from Inducing Epidermal Growth Factor Receptor

S. Dunn, M. Bally, P. Mertens, 2007, Molecular Pharmacology.

HER-2/neu overexpression increases the viable hypoxic cell population within solid tumors without causing changes in tumor vascularization.

K. Gelmon, M. Bally, Yanping Hu, 2004, Molecular cancer research : MCR.

Development and assessment of conventional and targeted drug combinations for use in the treatment of aggressive breast cancers.

D. Huntsman, K. Gelmon, S. Dedhar, 2006, Current cancer drug targets.

Tuning the Surface Chemistry of Second-Harmonic-Active Lithium Niobate Nanoprobes Using a Silanol-Alcohol Condensation Reaction.

B. Gates, D. Yapp, Henry Kang, 2021, Langmuir : the ACS journal of surfaces and colloids.

The involvement of insulin-like growth factor 2 binding protein 3 (IMP3) in pancreatic cancer cell migration, invasion, and adhesion

D. Yapp, Clarissa C. Pasiliao, S. Ng, 2015, BMC Cancer.

In Vivo Validation of PAPSS1 (3′-phosphoadenosine 5′-phosphosulfate synthase 1) as a Cisplatin-sensitizing Therapeutic Target

W. Lockwood, J. Berman, M. Bally, 2017, Clinical Cancer Research.

Cancer Therapy: Preclinical InVivoValidationofPAPSS1(30-phosphoadenosine 50-phosphosulfate synthase 1) as a Cisplatin- sensitizing Therapeutic Target

Eld, W. Lockwood, J. Berman, 2017 .

Routes to ruthenium(II) bromo(sulfoxide) complexes, including the synthesis and structural characterization of a neutral dilithium/diruthenium(II) complex containing terminal and bridging tetramethylene sulfoxide ligands

S. Rettig, D. Yapp, B. James, 1993 .